211 related articles for article (PubMed ID: 16391855)
1. Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models.
Kawai S; Yoshimura Y; Iida S; Kinoshita Y; Koishihara Y; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
Oncol Rep; 2006 Feb; 15(2):361-7. PubMed ID: 16391855
[TBL] [Abstract][Full Text] [Related]
2. Construction of a conventional non-radioisotope method to quantify HM1.24 antigens: correlation of HM1.24 levels and ADCC activity of the humanized antibody against HM1.24.
Kawai S; Koishihara Y; Iida S; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
Leuk Res; 2006 Aug; 30(8):949-56. PubMed ID: 16473407
[TBL] [Abstract][Full Text] [Related]
3. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
4. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody.
Wang W; Nishioka Y; Ozaki S; Jalili A; Abe S; Kakiuchi S; Kishuku M; Minakuchi K; Matsumoto T; Sone S
Cancer Immunol Immunother; 2009 Jun; 58(6):967-76. PubMed ID: 18979097
[TBL] [Abstract][Full Text] [Related]
5. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
6. Antigen-dependent internalization is related to rapid elimination from plasma of humanized anti-HM1.24 monoclonal antibody.
Amano J; Masuyama N; Hirota Y; Tanaka Y; Igawa Y; Shiokawa R; Okutani T; Miyayama T; Nanami M; Ishigai M
Drug Metab Dispos; 2010 Dec; 38(12):2339-46. PubMed ID: 20823293
[TBL] [Abstract][Full Text] [Related]
7. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
8. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
[TBL] [Abstract][Full Text] [Related]
9. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
10. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
Ishiguro T; Sugimoto M; Kinoshita Y; Miyazaki Y; Nakano K; Tsunoda H; Sugo I; Ohizumi I; Aburatani H; Hamakubo T; Kodama T; Tsuchiya M; Yamada-Okabe H
Cancer Res; 2008 Dec; 68(23):9832-8. PubMed ID: 19047163
[TBL] [Abstract][Full Text] [Related]
11. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
12. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
[TBL] [Abstract][Full Text] [Related]
13. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells.
Ohtomo T; Sugamata Y; Ozaki Y; Ono K; Yoshimura Y; Kawai S; Koishihara Y; Ozaki S; Kosaka M; Hirano T; Tsuchiya M
Biochem Biophys Res Commun; 1999 May; 258(3):583-91. PubMed ID: 10329429
[TBL] [Abstract][Full Text] [Related]
14. A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients.
Ishiguro T; Kawai S; Habu K; Sugimoto M; Shiraiwa H; Iijima S; Ozaki S; Matsumoto T; Yamada-Okabe H
Cancer Sci; 2010 Oct; 101(10):2227-33. PubMed ID: 20701608
[TBL] [Abstract][Full Text] [Related]
15. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.
Ishii T; Ishida T; Utsunomiya A; Inagaki A; Yano H; Komatsu H; Iida S; Imada K; Uchiyama T; Akinaga S; Shitara K; Ueda R
Clin Cancer Res; 2010 Mar; 16(5):1520-31. PubMed ID: 20160057
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor activity in xenograft model of multiple myeloma.
Tsunenari T; Akamatsu K; Kaiho S; Sato K; Tsuchiya M; Koishihara Y; Kishimoto T; Ohsugi Y
Anticancer Res; 1996; 16(5A):2537-44. PubMed ID: 8917348
[TBL] [Abstract][Full Text] [Related]
17. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
18. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
[TBL] [Abstract][Full Text] [Related]
19. In vivo assay of human NK-dependent ADCC using NOD/SCID/gammac(null) (NOG) mice.
Shiokawa M; Takahashi T; Murakami A; Kita S; Ito M; Sugamura K; Ishii N
Biochem Biophys Res Commun; 2010 Sep; 399(4):733-7. PubMed ID: 20696130
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.
Cardarelli PM; Moldovan-Loomis MC; Preston B; Black A; Passmore D; Chen TH; Chen S; Liu J; Kuhne MR; Srinivasan M; Assad A; Witte A; Graziano RF; King DJ
Clin Cancer Res; 2009 May; 15(10):3376-83. PubMed ID: 19401346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
